Ruixin Smart Medical

Name

Ruixin Smart Medical

Legal name

深圳睿心智能医疗科技有限公司

Website

https://raysightmed.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Ruixin Smart Medical (睿心医疗) is a Shenzhen-based medical device company that sells an integrated AI and surgical-robotics platform for cardiovascular diagnosis and interventional treatment to Chinese tertiary hospitals, with six products across CT-FFR, intraoperative FFR+IMR, planning, robotic PCI, and ICE imaging.

Ownership category

akta.pro rank

Product category

Interventional Cardiology Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

akta.pro secondary industries

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF), Healthcare & Assistive Robotics (HDAAAIAC), Surgical, Perioperative & ERAS Pathway Tools (HLACAGAJ)

Keywords

• Cardiovascular medical devices
• AI medical imaging
• Interventional cardiology
• Surgical robotics
• Non-invasive cardiac assessment

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales (AI Diagnostic Systems & Surgical Robotics): Revenue generated from selling AI-powered medical diagnostic devices and surgical robotics systems to hospitals. The company holds 11 NMPA registrations and 1 EU CE registration, enabling commercial sales of multiple product lines including RuiXin-FFR, AngioQFA, surgical robots, and ICE systems.
2. Clinical Collaboration Services: Revenue from clinical research collaborations with hospitals (50+ product research collaborations) and medical AI solutions deployed in healthcare institutions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Ruixin Smart Medical develops and sells an integrated AI plus surgical robotics platform for cardiovascular and cerebrovascular diagnosis and treatment. Its product portfolio covers the full coronary workflow: non-invasive CT-based FFR diagnosis (RuiXin-FFR), intelligent CT processing (Smart Pulse), pre-operative planning (RuiXin-Planner), intraoperative functional assessment combining macro FFR and micro IMR (AngioQFA), intracardiac echocardiography (ICE), and a fully automated AI-driven vascular interventional surgery robot capable of voice-command PCI execution with 5G remote surgery support.

Differentiator

Problem solved

Functional benefit

Brands

• 睿心分数 (RuiXin-FFR): Global first CT-FFR product integrating 'morphology' and 'functional diagnosis'
• 睿心智慧脉
• 睿心AngioQFA
• 睿心血管介入手术机器人
• 心腔内超声诊断系统 (ICE)

Products and services

• RuiXin-FFR (睿心分数) World's first CT-FFR product that integrates both morphological and functional assessment of coronary arteries, providing non-invasive coronary artery disease diagnosis through AI-powered analysis of CT angiography images. Designed for hospitals and cardiology departments performing coronary disease evaluation.
• RuiXin Smart Pulse (睿心智慧脉) Coronary CT intelligent processing software that automates analysis and interpretation of coronary CT scan data using AI algorithms, intended for hospitals and imaging centers processing coronary CT angiography studies.
• RuiXin-AngioQFA (睿心AngioQFA) One-stop intraoperative coronary function assessment system combining macro-level FFR (Fractional Flow Reserve) and micro-level IMR (Index of Microcirculatory Resistance) evaluation in a single procedure, intended for cardiac catheterization labs performing PCI.
• RuiXin-Planner (睿心术前手术方案规划系统) Pre-operative surgical planning system that enables detailed planning and simulation of coronary interventions before actual procedures, designed for interventional cardiologists preparing PCI cases.
• Vascular Interventional Surgery Robot (全自动AI血管介入手术机器人) Fully automatic AI-driven vascular interventional surgery robot system that executes PCI (Percutaneous Coronary Intervention) procedures autonomously based on operator voice commands, featuring master-slave control, precision force feedback, real-time visual feedback, and 5G remote surgery capability. Sold to hospitals and cardiac surgery centers performing coronary interventions.
• RuiXin ICE (心腔内超声诊断系统) Intracardiac Echocardiography (ICE) diagnostic system designed for electrophysiology and structural heart procedures, providing real-time intraoperative visualization of cardiac structures. Pre-market clinical trials initiated in 2025.

Quantifiable outcome

• 200,000+ patients safely treated with company products
• +4 more outcomes

Named customers21 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• 中国心血管医生创新俱乐部 (CCI)coreStrategic or Co-development PartnerStrategic collaboration with China Cardiovascular Physicians Innovation Club for product development and clinical innovation in cardiovascular interventions.
• 中国科学院深圳先进技术研究院coreStrategic or Co-development PartnerResearch collaboration with Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences for AI and robotics technology development.
• 深圳理工大学minorStrategic or Co-development PartnerAcademic partnership with Shenzhen University of Science and Technology for talent development and research collaboration.
• 复旦大学附属中山医院coreChannel Partner/ Reseller/ DistributorClinical collaboration hospital partner. Top-tier cardiovascular center serving as key clinical trial and research site for Ruixin products.
• 中国医学科学院阜外医院coreChannel Partner/ Reseller/ DistributorClinical collaboration hospital partner. Fuwai Hospital is China's premier cardiovascular hospital and serves as key clinical validation site.
• 四川大学华西医院coreChannel Partner/ Reseller/ DistributorClinical collaboration hospital partner. West China Hospital is one of China's largest and most prestigious hospitals, serving as clinical research site.

Scale indicators8 records

Emerging players

• Robocath: Robocath develops the R-One robotic platform for coronary interventions. As a focused European vascular robotics player, it is an emerging peer in the same robotic PCI category Ruixin targets.

Direct peers

• ArteryFlow Technology: ArteryFlow is a Chinese developer of computational FFR and coronary imaging AI products. It directly competes with Ruixin's FFR/IMR diagnostics in the Chinese hospital market.
• Corindus (Siemens Healthineers): Corindus, now part of Siemens Healthineers, develops vascular interventional robotics for PCI procedures. It is the most established peer in the robotic PCI category Ruixin is targeting.
• Stereotaxis: Stereotaxis provides robotic systems for electrophysiology and vascular interventional procedures. It overlaps with Ruixin's ambitions around robotic and image-guided cardiovascular intervention.
• HeartFlow: HeartFlow pioneered non-invasive CT-FFR analysis for coronary artery disease and is the original global leader in this category. Ruixin's RuiXin-FFR is a direct competing product targeting similar diagnostic use cases in cardiology.
• Shukun Technology: Shukun is a leading Chinese AI medical imaging company with strong cardiovascular imaging offerings. It is a direct domestic competitor in AI-powered cardiac diagnostics and shares Chinese hospital GTM dynamics.

Broad incumbents

• GE HealthCare: GE HealthCare offers cardiac CT, interventional imaging, and AI-enabled cardiology solutions. It is a broad incumbent with established hospital relationships that compete against Ruixin across multiple product lines.
• Philips: Philips is a global leader in cardiac imaging and has integrated FFR-CT-like capabilities through its Azurion and IntelliSpace platforms. It represents a broad incumbent competing across Ruixin's imaging and procedural portfolio.
• Siemens Healthineers: Siemens owns Corindus for vascular robotics and offers broad cardiovascular imaging products. It competes with Ruixin across diagnostics and interventional robotics as a diversified global incumbent.
• MicroPort Scientific: MicroPort is a leading Chinese cardiovascular device company with broad interventional cardiology portfolios. It shares the Chinese hospital GTM environment and competes in adjacent cardiovascular categories.

Market position

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ruixin Smart Medical